Back to discover
Drug

Sparsentan

Approved medicine
ClassType-1 angiotensin II receptor antagonistResearchOngoing clinical research

Also known as Filspari.

RxNorm2630535ChEMBLCHEMBL539423ATCC09XX01UNII9242RO5URM
6
Active clinical trials
2
Protein targets
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)

Clinical trial2026-06-23Results expected Q1 2027 · ClinicalTrials.gov

A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy

Clinical trial2026-06-03Results expected Q4 2027 · ClinicalTrials.gov

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Clinical trial2026-05-18Results expected Q4 2026 · ClinicalTrials.gov

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases

Clinical trial2026-05-12Results expected Q1 2027 · ClinicalTrials.gov

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

Clinical trial2026-04-20Results posted · ClinicalTrials.gov

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

Clinical trial2026-04-17Results posted · ClinicalTrials.gov

A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Clinical trial2025-11-20Results posted · ClinicalTrials.gov

Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC)

Clinical trial2024-07-18Primary completion · ClinicalTrials.gov

Approval: Filspari (EMA)

Regulatory2024-04-19EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sparsentan
Aliases & brands
Filspari
RxNorm CUI
2630535
ChEMBL ID
CHEMBL539423
ATC codes
C09XX01
UNII
9242RO5URM
Primary mechanism
Type-1 angiotensin II receptor antagonist
Regulatory jurisdictions
ema

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Type-1 angiotensin II receptor
AGTR1 · P30556
ANTAGONISTType-1 angiotensin II receptor antagonist
Endothelin-1 receptor
EDNRA · P25101
ANTAGONISTEndothelin receptor ET-A antagonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2024-04-19
Latest approval
2024-04-19
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2024-04-19Approval
Approval: Filspari (EMA)
Indication: Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine… Show full indication

Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2026
6
Active studies
3
Recruiting
3
Late-stage (III+)
2
Completed
PHASE DISTRIBUTIONn = 8
Phase 11Phase 24Phase 32Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)

Active, not recruitingPH IVTravere Therapeutics, Inc.n=202027

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

Active, not recruitingPH IIITravere Therapeutics, Inc.n=4062026

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

CompletedPH IIITravere Therapeutics, Inc.n=3712026
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.